Precision BioSciences, Inc. (DTIL)

10,72 -0,12 (-1,11%) A partir del 11:59AM EDT. Mercado abierto.

Precision BioSciences, Inc.

302 East Pettigrew Street
Suite A-100
Durham, NC 27701
United States
919 314 5512
https://www.precisionbiosciences.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 109

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Michael Amoroso	President, CEO & Director	1,07M	N/A	1978
Mr. John Alexander Kelly R.Ph.	CFO & Principal Accounting Officer	660,91k	N/A	1967
Dr. Alan F. List M.D.	Chief Medical Officer	692,17k	N/A	1955
Dr. Jefferson J. Smith Ph.D.	Co-Founder & Chief Research Officer	N/A	N/A	1973
Mei Burris	Director of Investor Relations & Finance	N/A	N/A	N/A
Mr. Dario Scimeca	General Counsel & Secretary	576,43k	N/A	1975
Mr. Bruce Stevens	Vice President of Quality & Compliance	N/A	N/A	N/A
Maurissa Messier	Senior Director of Corporate Communications	N/A	N/A	N/A
Ms. Juli Blanche	Chief People Officer	N/A	N/A	N/A
Mr. Garrett Gincley	Head of Manufacturing	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Gobierno corporativo

El ISS Governance QualityScore de Precision BioSciences, Inc., a día 1 de mayo de 2024, es 7. Las puntuaciones base son Auditoría: 4; Tablero: 7; Derechos de los accionistas: 8; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.